Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Heftler

Physical Medicine & Rehabilitation Greenwich, CT Medical Doctor

NPI 1639142128 CMS profile 1064474

6 Greenwich Office Park, Greenwich, CT 06831

Open in the dashboard

General payments

$679

10 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Heftler of Greenwich, CT is reported in the CMS Open Payments database as having received $679 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $368 5
2024 General $96 1
2019 General $215 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Heftler
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Jeffrey Heftler were reported at $368. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Jeffrey Heftler Physical Medicine & Rehabilitation median Middle half National median
2019 $215 $133 $45–$390 $163
2020 $0 $88 $29–$272 $114
2021 $0 $116 $33–$360 $132
2022 $0 $123 $40–$378 $149
2023 $0 $131 $43–$396 $160
2024 $96 $141 $45–$409 $164
2025 $368 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stratus Medical, LLC $272 2 payments
  2. Nevro Corp. $175 2 payments
  3. SPR Therapeutics, Inc $96 1 payment
  4. Pacira Pharmaceuticals Incorporated $54 1 payment
  5. Ferring Pharmaceuticals Inc. $29 2 payments
  6. Vertex Pharmaceuticals Incorporated $27 1 payment
  7. Flexion Therapeutics, Inc. $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $679 10 payments
Products named General payments · program years 2019–2025
  1. Nimbus $272 2 payments
  2. Senza Spinal Cord Stimulation System $175 2 payments
  3. SPRINT PNS System $96 1 payment
  4. Iovera $54 1 payment
  5. Zilretta Pain Management $54 1 payment
  6. Exparel $54 1 payment
  7. EUFLEXXA $29 2 payments
  8. JOURNAVX $27 1 payment
  9. Zilretta musculoskeletal $27 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

197

Median for Interventional Pain Management: 1,220

Drug cost

$1,945

Median for Interventional Pain Management: $39,344

Branded share of claims

0%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 48 $687
Pregabalin Generic 47 $661
Methylprednisolone Generic 73 $472
Meloxicam Generic 29 $124

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$212,523

Of which drugs: $31,398

Medicare patients

702

Average age 77

Services billed

14,050

438 women, 264 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 66%
Ischemic heart disease 24%
Osteoporosis 22%
Diabetes 20%
Cancer 19%
Atrial fibrillation 18%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 59 234 $21,726
Injection, methylprednisolone acetate, 1 mg J1010 Office 205 9,940 $1,011
Injection, methylprednisolone acetate, 40 mg J1030 Office 74 88 $376

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record